Cancer and blood coagulation (original) (raw)

Abstract.

In human patients, blood coagulation disorders often associate with cancer, even in its early stages. Recently, in vitro and in vivo experimental models have shown that oncogene expression, or inactivation of tumour suppressor genes, upregulate genes that control blood coagulation. These studies suggest that activation of blood clotting, leading to peritumoral fibrin deposition, is instrumental in cancer development. Fibrin can indeed build up a provisional matrix, supporting the invasive growth of neoplastic tissues and blood vessels. Interference with blood coagulation can thus be considered as part of a multifaceted therapeutic approach to cancer.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Division of Molecular Oncology, Institute for Cancer Research and Treatment (IRCC), University of Turin Medical School, Str. Prov. 142, 10060, Candiolo, Italy
    C. Boccaccio
  2. Oncogenomics Center, Institute for Cancer Research and Treatment (IRCC), University of Turin Medical School, Str. Prov. 142, 10060, Candiolo, Italy
    E. Medico

Authors

  1. C. Boccaccio
    You can also search for this author inPubMed Google Scholar
  2. E. Medico
    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toC. Boccaccio.

Additional information

Received 30 November 2005; received after revision 7 February 2005; accepted 8 February 2006

Rights and permissions

About this article

Cite this article

Boccaccio, C., Medico, E. Cancer and blood coagulation.Cell. Mol. Life Sci. 63, 1024–1027 (2006). https://doi.org/10.1007/s00018-005-5570-9

Download citation

Keywords.